CBPO  China Biologic Products Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

+0.86 (+1.31%)

Growth Price

Overvalued by 53.44%

Stability Price

Overvalued by 70.92%

Company Metrics

  • 25.94 P/E
  • 7.12 P/S
  • 8.36 P/B
  • 2.538 EPS
  • 40.69% Cash ROIC
  • 2.38 Cash Ratio
  • 0.00 / N/A % Dividend
  • 68,672.00 Avg. Vol.
  • 1.645B Market Cap.

Company Description

China Biologic Products, Inc., a biopharmaceutical company, engages in the research, development, production, and manufacture of plasma-based pharmaceutical products in the People's Republic of China. It offers Human Albumin for the treatment of shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Update: China Biologic Products Q3 Earnings Beat (CBPO)
Seeking Alpha (registration) - Nov 6, 2014
Before Q2 earnings on August 5, I wrote a bullish article on China Biologic Products (NASDAQ:CBPO), with a thesis stating that the company's plasma-based products should benefit from increasing market demand in China for Q2. I argued that the company's ...
China Biologic Products Becomes Oversold (CBPO)
Forbes - Oct 13, 2014
In trading on Monday, shares of China Biologic Products Inc (NASD: CBPO) entered into oversold territory, hitting an RSI reading of 29.1, after changing hands as low as $49.11 per share.
China Biologic Products, Inc. (CBPO) Rises: Stock Jumps 7.4%
Zacks.com - Aug 27, 2014
China Biologic Products, Inc. (CBPO) was a big mover last session, as the company saw its shares rise more than 7% on the day.
Protalix BioTherapeutics, Inc. (PLX) Jumps: Stock Adds 8.3% in Session - Tale ... - NASDAQ
China Biologic Products Earnings Preview (CBPO)
Seeking Alpha (registration) - Aug 5, 2014
After all, it seems that China remains largely untapped due to the lack of cultural awareness of Haemophilia. But, given that China Biologic Products is domestic to China, I suspect the company's efforts to improve cultural awareness could be effective.
China Biologic Products' (CBPO) CEO David Gao on Q3 2014 Results ...
Seeking Alpha (registration) - Nov 11, 2014
Hello, everyone and thank you for joining us on today's call. China Biologic announced its quarterly financial results on November 5 after the market closed.
China Biologic to Build Two New Plasma Collection Stations in Hebei Province
PR Newswire (press release) - Nov 3, 2014
BEIJING, Nov. 3, 2014 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its majority-owned subsidiary ...
Sector Update: Health Stocks Flat Pre-Bell - Nasdaq
China Biologic Products (CBPO) CEO David Gao on Q2 2014 Results - Earnings ...
Seeking Alpha (registration) - Aug 11, 2014
China Biologic Products (CBPO) CEO David Gao on Q2 2014 Results - Earnings Call Transcript. Aug. 10, 2014 10:18 PM ET | About: China Biologic Products, Inc. (CBPO) by: SA Transcripts. China Biologic Products, Inc. (NASDAQ:CBPO). Q2 2014 Earnings ...
Six Reasons to Buy China Biologic Products
Seeking Alpha - Oct 20, 2010
China Biologic used to have only one operating subsidiary, Shandong Taibang. By the end of 2008, with the acquisition of Guiyang Dalin and a 35% equity interest in Xi'an Huitian, China Biologic became the largest non-state owned company in China's ...
Why China Biologic Products (CBPO) Could Be an Impressive Growth Stock
Zacks.com - Aug 19, 2014
Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors' attention, and produce big gains as well.
China Biologic Products (CBPO) Adopts 'Poison Pill' Provision
StreetInsider.com (subscription) - Nov 19, 2012
China Biologic Products, Inc. (Nasdaq: CBPO) has adopted a stockholder rights plan. Pursuant to the plan, the Company will issue a dividend of one right for each share of its common stock held of record by stockholders as of the close of business on ...